J&J COVID-19 vaccine candidate protects monkeys after single dose

Rather than building its COVID-19 vaccine candidate with mRNA—the new technology that rivals Moderna and Pfizer have turned to—Johnson & Johnson selected an older vaccine platform that had proven to be safe in diseases like HIV and Ebola. Now, it’s reporting that a single dose of the vaccine protected nonhuman primates in a preclinical study.